Clinical Trial Update: Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of paclitaxel, carboplatin, and BSI-201 in advanced, persistent, or recurrent uterine carcinosarcoma has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Carcinosarcoma

Drugs mentioned

• BSI-201 (Iniparib) (iniparib)
• Carboplatin (Paraplatin) (carboplatin)
• Paclitaxel (Taxol) (paclitaxel)

Snippet

Sponsor: Sanofi | Conditions: Uterine Carcinosarcoma | Phase 2 | Status: COMPLETED